Efficient and reliable scale-up is one of the major hurdles in modern biotechnology. Engineering parameters such as impeller tip speed, oxygen transfer rate, impeller power number (Np) and the impeller power consumption per volume (P/V) are just a few of the parameters that need to be considered to ensure a successful tech transfer from bench to pilot and production scale. The BioFlo® 720 bioreactor control system was designed to save time and to mitigate risks.
Visus Therapeutics cashes in €20m from LSP
Latest NewsVisus Therapeutics has baged a €20m stock financing to advance development of Brimochol for presbyopia
Protein may help control cancer cells
Latest NewsThe protein eIF4A3 may hold the key for future cancer treatments, Karolinska researchers find.
British drug developer Mission Therapeutics plc earns $20m milestone
Latest NewsBritish drug developer Mission Therapeutics plc has bagged a $20m milestone payment from Abbvie within the companies’ neurodegenerative disease collaboration.
Bayer takes over Vividion
Latest NewsThe big pharma company is shelling out US$1.5bn in the acquisition of US screening specialist Vividion Therapeutics.
The Ongoing Pandemic Requires Completed SARS-CoV-2 Testing Solutions
ProductsSpectricity raises €14m in Series B round
Latest NewsBelgian semiconductor specialist Spectricity BV has baged €14m to speed up the development of mobile hyperspectral sensors for medical applications.
Sanofi snaps up mRNA partner for US$3.2bn
Latest NewsSanofi further launches into the messenger RNA space with US$3.2bn buy-out of mRNA pioneer Translate Bio.
BioFlo® 720: Experience Seamless Scalability of Your Bioprocess
ProductsEfficient and reliable scale-up is one of the major hurdles in modern biotechnology. Engineering parameters such as impeller tip speed, oxygen transfer rate, impeller power number (Np) and the impeller power consumption per volume (P/V) are just a few of the parameters that need to be considered to ensure a successful tech transfer from bench to pilot and production scale. The BioFlo® 720 bioreactor control system was designed to save time and to mitigate risks.
Abcam to acquire BioVision for $340m
Latest NewsLife sciences tool provider Abcam plc has entered into a definitive agreement to acquire BioVision, Inc. for $340m.
Vaccine development – strategic approach
Sponsored PublicationsThis white paper explores vaccine development during a pandemic, a response to complex challenges that traditional manufacturing methods won’t solve.